FEED:NASDAQENvue Medical, Inc. Analysis
Data as of 2026-09-29 - not real-time
$0.43
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $0.4320, ENvue Medical, Inc. shows a bearish moving-average alignment, with shorter averages beneath longer ones. Over a rolling month the price has lost 91.8%. RSI sits at 17.7, which reads as oversold, and MACD momentum is bearish. The recent range runs from support at $0.3650 up to resistance at $4.62.
Revenue is contracting at 51.6%.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 361.2%, a beta of 0.52 and a maximum drawdown of 99.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.
Revenue is contracting at 51.6%.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 361.2%, a beta of 0.52 and a maximum drawdown of 99.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.
Top Market Events
TYLER, Texas, Aug. 12, 2026 GLOBE NEWSWIRE -- ENvue Medical, Inc. NASDAQ: FEED "ENvue" or the "Company" , a...TYLER, Texas, Sept. 02, 2026 GLOBE NEWSWIRE -- ENvue Medical NASDAQ: FEED “ENvue” or the “Company” , a...Envue Medical Selected To Exhibit Envuetm Navigation Platform At Vizient Innovative Technology Exchange.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked below long-term ones
- RSI at 17.7 signals oversold conditions
- Trading below the 200-day average of 16.26
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked below long-term ones
- RSI at 17.7 signals oversold conditions
- Trading below the 200-day average of 16.26
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Negative return on equity of -59.1%
- Revenue contracting at -51.6%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
Revenue Growth-51.60%
ROE-59.14%
ROA-20.99%
Debt/Equity4.26
P/B Ratio0.0
Op. Cash Flow$-11649000
Free Cash Flow$-5824500
Industry P/E30.3
Technical Analysis
TrendBearish
RSI17.7
Support$0.37
Resistance$4.62
MA 20$2.26
MA 50$3.65
MA 200$16.26
MACDBearish
VolumeIncreasing
Fear & Greed Index92.21
Valuation
GradeFair
TypeBlend
Risk Assessment
Beta0.52
Volatility361.19%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.